Trial · NCT00484315

TAXUS PERSEUS Workhorse

NCT00484315, Phase 3, Completed, Boston Scientific Corporation; results first posted 2011-06-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. TAXUS PERSEUS Workhorse. Trials, record NCT00484315. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00484315

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: TAXUS PERSEUS Workhorse
NCT number: NCT00484315
Status: Completed
Phases: Phase 3
Enrollment: 1,264 participants, actual
Lead sponsor: Boston Scientific Corporation
Conditions: Coronary Artery Disease
Interventions: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
First posted: 2007-06-08
Last updated: 2014-05-08
Results first posted: 2011-06-28
Limitations and caveats: The comparator control for PERSEUS Workhorse study was chosen based on commercially available stent (TAXUS Express) at the time of study enrollment. Thus, the comparator group does not represent the most recently available paclitaxel-eluting stent.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.	12 months post-index procedure	The number of participants who experience a TLF through 365 days post-procedure out of the participants who have either had a TLF within 365 days post-procedure or who were TLF-free with last follow-up at least 335 days post-procedure.
Secondary	In-segment Percent Diameter Stenosis at 9 Months Post-index Procedure	9 months post-index procedure	The minimum lumen diameter in the analysis segment at 9-months post-index procedure, divided by the reference vessel diameter at baseline. The analysis segment ("in-segment") is defined as the proximal edge, stented area, and the distal edge, where each edge segment contains up to 5mm immediately outside the stent.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.	12 months post-index procedure	The primary analysis set for the non-inferiority testing of the primary endpoint, 12-month TLF, is the per protocol analysis set. All randomized participants who had the randomly assigned study stent implanted in the target coronary artery are included.	participants	NUMBER
SECONDARY	In-segment Percent Diameter Stenosis at 9 Months Post-index Procedure	9 months post-index procedure	All patients from the per protocol analysis set who were randomized to the angiographic subset and completed their angiographic follow-up were analyzed for the secondary endpoint.	percent diameter stenosis	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.	TAXUS Element	51		participants
Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.	TAXUS Express	19		participants
In-segment Percent Diameter Stenosis at 9 Months Post-index Procedure	TAXUS Element	26.1	Standard Deviation 17.71	percent diameter stenosis
In-segment Percent Diameter Stenosis at 9 Months Post-index Procedure	TAXUS Express	26.28	Standard Deviation 17.6	percent diameter stenosis

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
12-Month Clinical Follow-up	STARTED	TAXUS Element	942
12-Month Clinical Follow-up	STARTED	TAXUS Express	320
12-Month Clinical Follow-up	COMPLETED	TAXUS Element	914
12-Month Clinical Follow-up	COMPLETED	TAXUS Express	311
12-Month Clinical Follow-up	NOT COMPLETED	TAXUS Element	28
12-Month Clinical Follow-up	NOT COMPLETED	TAXUS Express	9
9-Month Angiographic Follow-up	STARTED	TAXUS Element	256
9-Month Angiographic Follow-up	STARTED	TAXUS Express	74
9-Month Angiographic Follow-up	COMPLETED	TAXUS Element	228
9-Month Angiographic Follow-up	COMPLETED	TAXUS Express	61

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events516

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Angina pectoris	Cardiac disorders	TAXUS Element	98	942	114
other	Angina pectoris	Cardiac disorders	TAXUS Express	40	320	44
other	Catheter site haematoma	General disorders	TAXUS Element	46	942	47
other	Catheter site haematoma	General disorders	TAXUS Express	19	320	22
other	Catheter site haemorrhage	General disorders	TAXUS Element	28	942	28
other	Catheter site haemorrhage	General disorders	TAXUS Express	16	320	18
other	Non-cardiac chest pain	General disorders	TAXUS Element	120	942	150
other	Non-cardiac chest pain	General disorders	TAXUS Express	32	320	36
other	Back pain	Musculoskeletal and connective tissue disorders	TAXUS Element	55	942	56
other	Back pain	Musculoskeletal and connective tissue disorders	TAXUS Express	18	320	19

1 to 10 of 516Source ClinicalTrials.gov

See all 516 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	TAXUS Element
Total, all-cause mortality	TAXUS Express
Total, other adverse events	TAXUS Element	277	942
Total, other adverse events	TAXUS Express	97	320
Total, serious adverse events	TAXUS Element	334	942
Total, serious adverse events	TAXUS Express	110	320

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
20059766	DERIVED	PubMed
20493653	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
TAXUS Element vs TAXUS Express: Target Lesion Failure (TLF) at 12 Months Post-index Procedure. TLF is Defined as Any Ischemia-driven Revascularization of the Target Lesion, Myocardial Infarction (Q-wave and Non-Q-wave), or Death Related to the Target Vessel.	Trial comparisons
TAXUS Element vs TAXUS Express: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00484315

GET https://conductscience.org/api/trials/v1/NCT00484315/events?page=2

API reference For AI assistants